- Report
- April 2022
- 120 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- May 2023
- 450 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- October 2018
- 84 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- January 2022
- 176 Pages
Global
From €3060EUR$3,185USD£2,616GBP
€4372EUR$4,550USD£3,738GBP
- Report
- April 2019
- 186 Pages
Asia Pacific
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- April 2019
- 145 Pages
Europe
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- April 2019
- 155 Pages
North America
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- April 2019
- 145 Pages
Asia Pacific
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- June 2022
- 120 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- April 2023
- 120 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- June 2022
- 115 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- January 2022
- 120 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- July 2021
- 112 Pages
Global
From €4276EUR$4,450USD£3,656GBP
- Report
- January 2022
- 182 Pages
Global
From €3459EUR$3,600USD£2,957GBP
- Report
- August 2023
- 51 Pages
South Korea
From €577EUR$600USD£493GBP
- Report
- August 2023
- 51 Pages
Mexico
From €577EUR$600USD£493GBP
- Report
- August 2023
- 51 Pages
Canada
From €577EUR$600USD£493GBP
- Report
- August 2023
- 51 Pages
Saudi Arabia
From €577EUR$600USD£493GBP
From €577EUR$600USD£493GBP
- Report
- August 2023
- 51 Pages
Germany
From €577EUR$600USD£493GBP
The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more